An Open Label Randomized Comparative Clinical Study of Safoof-e-Mohazzil versus Atorvastatin in the Cases of Fart-e-Tadassum-Fid-Dam (Primary Hyperlipidaemia)

Abstract

Hyperlipidaemia (Fart-e-Tadassum-Fid-Dam) is a common metabolic disease seen in clinical practice. It is mentioned that increased lipid level is associated with the pathogenesis of atherosclerosis. Theory of hyperlipidaemia meets similarly on the basis of etiology, presentation, complications, patho-physiology and non-pharmacological management with Saman-e-mufrit (obesity). Therefore, it is an important need to provide safe and effective drug from Unani system of medicine for the long term management of hyperlipidaemia. In the present study, all patients were randomly divided in two groups (test group and standard group). The patients of test groups received Safoof-e-Mohazzil 05 gm OD in morning and standard group received Atorvastatin (Atorva) 10 mg OD (HS). After intervention, most of the subjective parameters improved significantly in both interventional groups. While comparing to the test group vs. standard group, improvement of subjective parameters did not differ significantly. On objective parameters, improvement is very significant in both groups. All the biochemical parameters in each intervention groups had P=0.001. On comparison between test group vs. standard group by using unpaired “t” test, test drug is more effective than control drug for the increment on HDLc, lowering of BMI and WHR. The HDL cholesterols are considered as good cholesterols and help in lowering of BMI and WHR, so this is also beneficial effect of test drug.

Keywords: Safoof-e-Mohazzil, Fart-e-Tadassum-Fid-Dam, primary hyperlipidaemia

Cite this Article Md Razi Ahmed, Md Najibur Rahman, Jamal Akhtar et al. An Open Label Randomized Comparative Clinical Study of Safoof-e-Mohazzil versus Atorvastatin in the Cases of Fart-e-Tadassum-Fid-Dam (Primary Hyperlipidaemia). Research & Reviews: A Journal of Unani, Siddha and Homeopathy. 2018; 5(1): 6–12p.